Erandamuladi Niruha Basti and Madhutailik Basti in the Management of Polycistic Ovarian Syndrome in the Reproductive age women.

RANDOMIZED COMPARATIVE CLINICAL TRIAL TO EVALUATE THE EFFECT OF ERANDAMULADI NIRUHA BASTI AND MADHUTAILIK BASTI IN THE MANAGEMENT OF POLYCYSTIC OVARIAN SYNDROME IN THE REPRODUCTIVE AGE WOMEN.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052924

Enrollment

140

Registered

2023-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome Health Condition 2: E282- Polycystic ovarian syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases ofPCOS (by Rotterdam criteria)- Any 2/3. a. Hyperandrogenism (Clinical or biochemical). b. Oligomenorrhea (menstrual cycle >35 days)/ Secondary amenorrhea (menstrual cycle >90 days but c. USG findings- PCO features on USG i.e. peripherally Arranged Antral Follicle Count >12 with thickened stroma in ovaries and/or Ovarian volume >10 cm 3 in Unilateral or Bilateral ovaries. Patient fit for basti.

Exclusion criteria

Exclusion criteria: A. Patient of age group 35years. B. Patients showing sign & symptoms other than PCOS. C. Patient having any other disease causing oligomenorrhea and anovulation excluding PCOS on above criteria i.e.Hypogonadotrophic hypogonadism, premature ovarian failure. D. Known cases of a) Congenital adrenal hyperplasia b) Severe insulin resistance (insulin dependent diabetes mellitus) c) Androgen secreting ovarian and adrenal tumors d) Thyroid abnormalities e) Cushing syndrome f) Cardiac disease g) Hyperprolactinemia. E. Patient with any organic lesions of reproductive tract like TB, CA, Congenital anomalies, any other pelvic pathologies. F. A current or previous (within 3 months) use of OC Pills, glucocorticoids, antiandrogens, antidiabetics, anti-obesity drugs or any hormonal therapy. G. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
Follicular growth (Ovulation)Timepoint: Baseline - 4 weeks, 8 weeks and 12 weeks	—

Secondary

Measure	Time frame
Hirsutism, Acne, Obesity (BMI), Hormonal estimationTimepoint: Baseline - 4 weeks, 8 weeks and 12 weeks	—

Countries

India

Contacts

Public ContactSANDHYA MADHUKAR YENNAWAR

PMTs Ayurved Medical College and Shri Eknath Ayurved Rugnalaya

prkanade73@gmail.com9881413123

Outcome results